Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

re approximately 475,000 people in the United States alone living with NHL (active disease or in remission).

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... nurses at New York University,s Langone Medical Center (NYULMC) ... the youngest and most vulnerable down flights of stairs ... generated by Hurricane Sandy. , Now, a recent ... of Nursing (NYUCN) and of Dentistry (NYUCD), published in ... impact on NYULMC nurses, post-Sandy deployment to help address ...
(Date:8/22/2014)... August 22, 2014 Human induced pluripotent ... of regenerative medicine because they can be coaxed to ... always act as anticipated. They sometimes mutate, develop into ... a new study recently published in STEM CELLS Translational ... this, simply by removing the material used to reprogram ...
(Date:8/22/2014)... low levels of nicotine may reduce addiction without ... new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours of ... of cigarettes with markedly reduced nicotine levels. , ... of which have very similar levels of nicotine ...
(Date:8/22/2014)... 2014 Lincolnshire Marriott Resort is inviting ... a tap, announcing Marriott’s new iPad Mini promotion for ... this exclusive offer will receive a complimentary iPad Mini ... the day’s agenda with ease. Marriott’s Meeting Services app, ... and connect with their group with just a few ...
Breaking Medicine News(10 mins):Health News:Many patients are discharged without a diagnosis 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:Lincolnshire Marriott Resort Offers iPad Mini for Chicago Meeting Planners 2
... Oct. 5 "The good news is,that there ... Terry D. Hashey,Medical Director of First Coast Family ... Corral Flu Campaign. "The bad news,is that despite ... still,ranked below the national average of 69.3% for ...
... dietary supplement ... LipidShield Plus(TM), MELBOURNE, Fla., Oct. ... has expanded again and LipidShield Plus(TM) is,now available at Stop & ... breakthrough cholesterol,fighting product that has been clinically proven to lower cholesterol ...
... Oct. 5 /Xinhua-PRNewswire/ -- In a star-studded ... Olympics honored twelve,extraordinary individuals and the city ... made and continue to make to promote ... of people with intellectual,disabilities, and the Special ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... Calif., Oct. 4 The Integrated Healthcare,Association ... to physician,groups in California at its annual ... 47 most outstanding physician groups were,honored for ... care,quality measures, including preventive care and chronic ...
... HealthShares(TM) Inc., an investment,company with a series ... been informed by Standard & Poor,s, the calculating ... at the opening of,trading on October 8, 2007, ... (NasdaqGS: FOXH) in the,HealthShares(TM) Cardio Devices Index. ...
Cached Medicine News:Health News:Florida Health Care Community Stepping Up for the 2007-2008 Flu Season 2Health News:New Health Corp. Announces the Addition of Stop & Shop and Giant Supermarkets to its Retail Outlets 2Health News:Special Olympics 'Special Spirit in China Award Of Excellence' Presented to Dedicated Friends of Special Olympics and City of Shanghai 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 3Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 4Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 3
... Novagen's Vacuum Manifold system for sample ... to which a vacuum is applied, a ... accessories for convenience in sample handling. The ... elution of up to 12 samples simultaneously. ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: